Is Oxyntomodulin FDA approved?

Oxyntomodulin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Cagrilintide administered in research settings?

In research settings, Cagrilintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Oxyntomodulin administered in research settings?

In research settings, Oxyntomodulin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cagrilintide vs Oxyntomodulin

Peptide Comparison

Cagrilintide vs Oxyntomodulin

Name: Cagrilintide vs Oxyntomodulin — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

Cagrilintide

AM833

Fat LossUnder clinical reviewResearch Only

Half-life: ~7 days

21 providers listed

Full Cagrilintide profile →

Oxyntomodulin

OXM

Fat LossInvestigationalResearch Only

No providers listed yet

Full Oxyntomodulin profile →

Bottom line

Cagrilintide carries stronger published evidence (Meta-analysis, 9 key studies) than Oxyntomodulin (RCT, 4); both are research compounds.

Quick Verdict

Cagrilintide

Half-life

~7 days

Oxyntomodulin

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cagrilintide
More provider options (21 vs 0)	Cagrilintide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cagrilintide

Oxyntomodulin

Mechanism Family

Metabolic

Half-life

~7 days

—

FDA Status

Under clinical review

investigational

Admin Routes

subcutaneous

subcutaneous, intravenous

Availability

Research Only

Providers

21 listed

None listed

Avail. Notes

Amylin analog by Novo Nordisk. Phase 3 as CagriSema (+ semaglutide, NCT05669755) for obesity. Not yet approved. NDA submission anticipated 2026-2027 if trials succeed.

—

Research Evidence

Cagrilintide

Meta-analysis · 9 key studies · most recent 2026

Oxyntomodulin

RCT · 4 key studies · most recent 2026

Research Citations

Cagrilintide

Meta-analysis2026 · Endocrinol Diabetes Metab

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…

RCT2026 · Lancet Diabetes Endocrinol

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…

RCT2023 · Lancet

Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…

RCT2021 · Lancet

Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…

+5 more

Oxyntomodulin

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2005 · Diabetes

Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects

Review2026 · Expert Opin Ther Pat

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity a…

Review2026 · Endocr Rev

Regulators of Appetite in Mammals - Old and New players.

About Cagrilintide

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

Research Areas

fat_loss

About Oxyntomodulin

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Research Areas

appetite suppressionenergy expenditurefat oxidation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cagrilintide

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

HbA1cFasting glucoseTSHCalcitoninLipaseeGFRALT/AST

Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.

Oxyntomodulin

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Price (per mg)

Cagrilintide

$10.00/mg

$7.98 – $14.55 range

23 vendors

View price index →Find providers →

Oxyntomodulin

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cagrilintide

21 listed

Browse directory →

Providers offering

Oxyntomodulin

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cagrilintide vs Oxyntomodulin — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/oxyntomodulin

https://peptidebase.io/peptides/compare/cagrilintide/oxyntomodulin Methodology License Download JSON Download CSV